About Monolom India Pharma Private Limited
Data last updated:
Monolom India Pharma Private Limited is a foreign private limited company based in Pune, Maharashtra, India, a subsidiary of Wavelength Enterprises Limited. It operates in the pharma contract r and d segment of the pharmaceuticals sector. It was incorporated on 27 October 2017 and has been in existence for over 9 years.
The company is registered with the Registrar of Companies (ROC), Pune, under CIN U24303PN2017FTC188118. Its GSTIN is 27AALCM4113E1ZP (Maharashtra).
The company has an authorised share capital of ₹5.3 Cr and a paid-up capital of ₹3.44 Cr. It is led by directors including Chiara Bergerone and Ben Zion Dolitzky.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 15 Intl Biotech Park, Pune, Maharashtra.
As per the financials filed for FY 2025, the company reported a revenue of ₹18.17 Cr, a decline of 1% compared to the previous year. For the same year it recorded a net profit of ₹2.04 Cr (net margin 11.2%) and EBITDA of ₹4.45 Cr (EBITDA margin 24.5%). Revenue has grown at a compounded annual rate (CAGR) of 5% over three years and 10% over five years.
The company has about 38 employees on its provident fund (EPFO) records.
The company is associated with 2 brands: Wavelength Pharmaceuticals and Seqens. As per MCA filings, the company has open charges of ₹50,000 on record. The company has 1 deal on record (1 rights issue); the latest was in January 2019. Its 5 peer companies in the Pharma industry (Contract Research), with the same principal business activity (scientific research and development) are compared by revenue, 2 larger and 3 smaller; the largest is Vipragen Biosciences Private Limited with revenue of ₹18.35 Cr. The company has 11 MSME Form 1 returns on record between 2019 and 2023, listing 383 overdue payments to 36 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website wavelengthpharma.com.
Company details
CIN history
Monolom India Pharma has one previous CIN (Corporate Identification Number): U24303MH2017FTC301208. The current CIN is U24303PN2017FTC188118, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24303PN2017FTC188118 | Current |
| U24303MH2017FTC301208 | Previous |
Contact details
Monolom India Pharma Private Limited's registered office is in Pune, Maharashtra. Its website is wavelengthpharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressNo.1 – 7&12 – 17 3 Floor Genesis Square Plot No.15 Intl Biotech Park MIDC Phase 2 Rg It Bt, Park Maan, Pune, Maharashtra, India – 411057
- IndustryPharma, Pharma Contract R&D
To see the full contact details of Monolom India Pharma Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Monolom India Pharma operates two associated brands: Wavelength Pharmaceuticals and Seqens. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| APIs and finished dosage forms are manufactured for therapeutic categories. | wavelengthpharma.com | |
| Contract manufacturing services for small molecules and peptides are provided. | seqens.com |
Business activity
The main business activity of Monolom India Pharma is professional, scientific and technical. In detail, this covers scientific research and development.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| M | Professional, Scientific and Technical | M5 | Scientific research and development |
To see the full business activity and turnover split of Monolom India Pharma Private Limited, buy the company report.
Financials of Monolom India Pharma Private Limited
FY 2025 filings availableMonolom India Pharma Private Limited reported revenue of ₹18.17 Cr (down 1% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue fell 1% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 10%. EBITDA fell 2% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹4.45 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹2.04 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 24.5% | ||||
| Net Profit Margin | 11.2% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Monolom India Pharma Private Limited, buy the company report.
Board of directors of Monolom India Pharma Private Limited
Monolom India Pharma has 4 current directors and 11 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Chiara Bergerone Also directs: Vanamali Organics Private Limited | Director | Current | ||
| Ben Zion Dolitzky | Director | 24 Mar 2023 | 3 Years 7 Months | Current |
| Ashutosh Vijay Joshi | Director | 30 Jun 2025 | 1 Years 4 Months | Current |
| Adrien Aymery Joel Bresson | Director | 22 Jan 2025 | 1 Years 9 Months | Current |
Peer comparison
Monolom India Pharma Private Limited is compared with the 5 companies closest to it by revenue in the Pharma industry (Contract Research), with the same principal business activity (scientific research and development), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Vipragen Biosciences Private Limited | ₹18.35 Cr (FY 2025) | 46.0% | Mysore, Karnataka, India | |||
| Vivancemed India Private Limited | ₹18.19 Cr (FY 2024) | 20.0% | Bangalore, Karnataka, India | |||
| Monolom India Pharma Private Limitedthis company | ₹18.17 Cr (FY 2025) | ₹2.04 Cr | 11.2% | -1.0% | 38 | Pune, Maharashtra, India |
| Finoso Pharma Private Limited | ₹17.69 Cr (FY 2025) | -7.0% | Hyderabad, Telangana, India | |||
| Semler Research Center Private Limited | ₹17.66 Cr (FY 2025) | 926.0% | Bengaluru, Karnataka, India | |||
| Sravathi Advance Process Technologies Private Limited | ₹17.29 Cr (FY 2025) | 40.0% | Bangalore, Karnataka, India |
To see the full peer comparison of Monolom India Pharma Private Limited, buy the company report.
Auditor
Monolom India Pharma Private Limited is audited by Sudit K. Parekh & Co. for the financial year 2022.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Sudit K. Parekh & Co. | FY 2022 | 110512W |
Shareholding
The shareholding of Monolom India Pharma Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Monolom India Pharma Private Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 23 Nov 2022 | 100654549 | The Hongkong and Shanghai Banking Corporation Limited | ₹50,000 | Open |
To see the full charge records of Monolom India Pharma Private Limited, buy the company report.
Total charge records: 1 View all charges
Deals & funding
Monolom India Pharma Private Limited has 1 deal on record (1 rights issue); the latest was in January 2019.
Deals on record (1 of 1)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jan 2019 | Rights issue | ₹5.14 Cr | Investors: Wavelength Enterprises Limited |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
No court or tribunal cases involving Monolom India Pharma Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
Monolom India Pharma Private Limited has 11 MSME Form 1 returns on record between 2019 and 2023, listing 383 overdue payments to 36 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 36)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| J P Enterprises | |||
| Pineapple Corporation Solutions LLP | |||
| Chromatography World | |||
| Ace Tech Mercantile LLP |
To see the full MSME payment records of Monolom India Pharma Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Monolom India Pharma Private Limited has a workforce of 38 employees on its EPFO records as of May 2026, across 1 active EPFO establishment.
Headcount by financial year
| Financial year | Employees (EPFO) |
|---|---|
| FY 2026-27 | 38 |
| FY 2025-26 | |
| FY 2024-25 | |
| FY 2023-24 | |
| FY 2022-23 | |
| FY 2021-22 | |
| FY 2020-21 | |
| FY 2019-20 | |
| FY 2018-19 | |
| FY 2017-18 |
To see the full employee and EPFO history of Monolom India Pharma Private Limited, buy the company report.
GST
Monolom India Pharma has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AALCM4113E1ZP | Maharashtra | Active | 23 May 2018 |
To see the full GST registrations and return filing status of Monolom India Pharma Private Limited, buy the company report.
Recent activity
Monolom India Pharma Private Limited has 14 board changes on record since 2017: 3 appointments and 11 cessations. The latest: Adrien Aymery Joel Bresson ceased to be Additional Director on 29 Sep 2025.
7 earlier events are in the company report.
News
Frequently asked questions
Monolom India Pharma is an active foreign private limited company based in Pune, Maharashtra, India. The company works in pharma contract r and d, within the pharma industry. It was incorporated on 27 October 2017 (9+ years old) and is registered under CIN U24303PN2017FTC188118.
Monolom India Pharma has 4 current directors:
- Chiara Bergerone - Director
- Ben Zion Dolitzky - Director
- Ashutosh Vijay Joshi - Director
- Adrien Aymery Joel Bresson - Director
The latest financial statements of Monolom India Pharma on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2018 are in the company report.
The GSTIN of Monolom India Pharma is 27AALCM4113E1ZP, registered in Maharashtra.
The CIN (Corporate Identification Number) of Monolom India Pharma is U24303PN2017FTC188118. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Monolom India Pharma was incorporated on 27 October 2017, making it 9+ years old. It is registered with the Registrar of Companies, Pune.
Monolom India Pharma has 1 deal on record (1 rights issue); the latest was in January 2019.
The peers of Monolom India Pharma by revenue are Vipragen Biosciences Private Limited, Vivancemed India Private Limited, Finoso Pharma Private Limited, Semler Research Center Private Limited, Sravathi Advance Process Technologies Private Limited, all in the Pharma industry (Contract Research), with the same principal business activity (scientific research and development).
Adrien Aymery Joel Bresson ceased to be Additional Director on 29 Sep 2025. Ashutosh Vijay Joshi ceased to be Additional Director on 29 Sep 2025. Ashutosh Vijay Joshi was appointed as Director on 30 Jun 2025. Monolom India Pharma has 14 board changes on record in total.
Monolom India Pharma has 11 MSME Form 1 returns on record between 2019 and 2023, listing 383 overdue payments to 36 micro and small suppliers. The latest return was filed on 21 Oct 2023.
Monolom India Pharma can be reached through the website wavelengthpharma.com. Its registered office is in Pune, Maharashtra, India.
The registered office of Monolom India Pharma is at No.1 – 7&12 – 17 3 Floor Genesis Square Plot No.15 Intl Biotech Park MIDC Phase 2 Rg It Bt, Park Maan, Pune, Maharashtra, India – 411057.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
